[Clinical evaluation of aztreonam for complicated urinary tract infection].

Efficacy and safety of Aztreonam, a monobactam antibiotic developed by E.R. Squibb & Sons, Inc. U.S.A., in complicated urinary tract infections (UTI) were studied. Aztreonam was administered to 15 patients with complicated UTI admitted to our Hospitals between July, 1984 and January, 1985. A two-gram dose of Aztreonam was administered twice a day intravenously or intraductally for 5 days consecutively. There were 11 evaluable cases in accordance with the UTI Drug Efficacy Evaluation Standard (the second issue). Overall clinical effect of these cases were "excellent" in 6 cases, "good" in 2 cases and "poor" in 3 cases. All the effective cases ("excellent" and "good") were of single infections and all the non-effective cases ("poor") were of complicated infections. All of the gram-negative pathogens and 4 of the 8 gram-positive pathogens were eliminated. In no cases were side effects or significantly abnormal laboratory findings reported. Therefore, Aztreonam is very effective and safe for complicated UTI, especially gram-negative infections.